 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...112113114115116117118119120121122123124» |
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: KEYNOTE 523: Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors (clinicaltrials.gov) - Apr 17, 2017
P1b, N=10, Recruiting, Sponsor: Eisai Co., Ltd.
Not yet recruiting --> Recruiting
- |||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China (clinicaltrials.gov) - Apr 17, 2017
P3, N=150, Recruiting, Sponsor: Eisai Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: KEYNOTE 524: A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 4, 2017
P1b, N=30, Recruiting, Sponsor: Eisai Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Trial initiation date, Trial primary completion date, Combination therapy, Metastases: A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease (clinicaltrials.gov) - Mar 13, 2017
P2, N=31, Recruiting, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Completed --> Recruiting | Initiation date: Jun 2013 --> Feb 2017 | Trial primary completion date: Feb 2016 --> Dec 2018
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Trial initiation date, Trial primary completion date, Combination therapy, Metastases: A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease (clinicaltrials.gov) - Mar 7, 2017
P2, N=27, Completed, Sponsor: Eisai Inc.
Completed --> Recruiting | Initiation date: Jun 2013 --> Feb 2017 | Trial primary completion date: Feb 2016 --> Dec 2018 Recruiting --> Completed | Initiation date: Feb 2017 --> Jun 2013 | Trial primary completion date: Dec 2018 --> Feb 2016
- | Opdivo (nivolumab) / Ono Pharma, BMS, lenvatinib / Generic mfg., Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Journal: Renal cell carcinoma: molecular characterization and evolving treatment paradigms. (Pubmed Central) - Mar 3, 2017
The addition of several new agents effective in metastatic RCC has resulted in improvements in overall survival; however, there are few avenues to durable responses or cure. Ongoing studies as well advances in our understanding of the molecular alterations underlying distinct forms of RCC promise further therapeutic advances and have the potential to alter the current treatment paradigm.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Trial initiation date, Combination therapy, Metastases: A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease (clinicaltrials.gov) - Feb 27, 2017
P2, N=31, Recruiting, Sponsor: Eisai Inc.
Ongoing studies as well advances in our understanding of the molecular alterations underlying distinct forms of RCC promise further therapeutic advances and have the potential to alter the current treatment paradigm. Not yet recruiting --> Recruiting | Initiation date: Nov 2016 --> Feb 2017
- | Journal: EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells. (Pubmed Central) - Feb 24, 2017
EGF could trigger resistance to RET inhibition in CCDC6-RET lung cancer cells, and endothelial cells may confer resistance to RET inhibitors by EGF. E7080 and other RET inhibitors may provide therapeutic benefits in the treatment of RET-positive lung cancer patients.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date, PD(L)-1 Biomarker: Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) (clinicaltrials.gov) - Jan 26, 2017
P2, N=60, Not yet recruiting, Sponsor: Academic and Community Cancer Research United
E7080 and other RET inhibitors may provide therapeutic benefits in the treatment of RET-positive lung cancer patients. Initiation date: Jan 2017 --> Apr 2017
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Surgery, Metastases: Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 3, 2017
P2, N=25, Not yet recruiting, Sponsor: Mayo Clinic
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial: Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor (clinicaltrials.gov) - Jan 3, 2017
P1, N=12, Not yet recruiting, Sponsor: Eisai Inc.
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Phase classification, Enrollment change: KEYNOTE-146: A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors (clinicaltrials.gov) - Dec 30, 2016
P1b/2, N=250, Recruiting, Sponsor: Eisai Inc.
Initiation date: Jan 2017 --> Apr 2017 Phase classification: P1/2 --> P1b/2 | N=150 --> 250
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial: KEYNOTE 523: Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors (clinicaltrials.gov) - Dec 30, 2016
P1b, N=10, Not yet recruiting, Sponsor: Eisai Co., Ltd.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial: KEYNOTE 524: A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma (clinicaltrials.gov) - Dec 30, 2016
P1b, N=30, Not yet recruiting, Sponsor: Eisai Co., Ltd.
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial: Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding (clinicaltrials.gov) - Dec 20, 2016
P0, N=52, Recruiting, Sponsor: Eisai Inc.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Enrollment change, Trial initiation date, Metastases: Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Dec 14, 2016
P1, N=22, Active, not recruiting, Sponsor: Eisai Inc.
Phase classification: P1/2 --> P1b/2 | N=150 --> 250 Recruiting --> Active, not recruiting | N=18 --> 22 | Initiation date: Jan 2016 --> May 2016
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open: Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (clinicaltrials.gov) - Nov 28, 2016
P1, N=210, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting | N=18 --> 22 | Initiation date: Jan 2016 --> May 2016 Not yet recruiting --> Recruiting
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, PD(L)-1 Biomarker: Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) (clinicaltrials.gov) - Nov 28, 2016
P2, N=60, Not yet recruiting, Sponsor: Academic and Community Cancer Research United
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P3 trial: A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China (clinicaltrials.gov) - Nov 17, 2016
P3, N=150, Not yet recruiting, Sponsor: Eisai Co., Ltd.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed: Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy (clinicaltrials.gov) - Nov 10, 2016
P2, N=26, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial: Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Nov 3, 2016
P1, N=24, Recruiting, Sponsor: Eisai Co., Ltd.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change: A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile (clinicaltrials.gov) - Nov 2, 2016
P2, N=41, Active, not recruiting, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting N=29 --> 41
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Trial primary completion date: A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) (clinicaltrials.gov) - Oct 25, 2016
P2, N=76, Recruiting, Sponsor: Eisai Inc.
N=29 --> 41 Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2018 --> Jul 2018
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer (clinicaltrials.gov) - Oct 25, 2016
P1, N=30, Recruiting, Sponsor: Floor Backes
Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2018 --> Jul 2018 Not yet recruiting --> Recruiting
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial, Metastases: Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma (clinicaltrials.gov) - Oct 16, 2016
P1, N=28, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- |||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Metastases: CLEAR trial: Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Sep 30, 2016
P3, N=735, Recruiting, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: Post-Marketing Surveillance of Lenvima in Korean Patients (clinicaltrials.gov) - Sep 29, 2016
P=N/A, N=3000, Recruiting, Sponsor: Eisai Korea Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Combination therapy, Metastases: A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease (clinicaltrials.gov) - Sep 27, 2016
P2, N=31, Not yet recruiting, Sponsor: Eisai Inc.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial, Metastases: Lenvatinib and Capecitabine in Patients With Advanced Malignancies (clinicaltrials.gov) - Sep 26, 2016
P1, N=46, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date, Metastases: CLEAR trial: Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Sep 19, 2016
P3, N=735, Not yet recruiting, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2020 --> Oct 2019
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Enrollment change: A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile (clinicaltrials.gov) - Aug 12, 2016
P2, N=29, Active, not recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Nov 2020 --> Oct 2019 Recruiting --> Active, not recruiting | N=210 --> 29
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14 (clinicaltrials.gov) - Aug 10, 2016
P2, N=26, Recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- ||| Keytruda (pembrolizumab) / Merck (MSD)
New P1 trial: Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (clinicaltrials.gov) - Aug 10, 2016
P1, N=210, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Pan tumor, Metastases: Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling (clinicaltrials.gov) - Jul 27, 2016
P2, N=39, Not yet recruiting, Sponsor: Teresa Helsten, MD
- | Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Trial initiation date, Metastases: Eribulin and Lenvatinib in Advanced Solid Tumors (clinicaltrials.gov) - Jul 23, 2016
P2, N=39, Recruiting, Sponsor: Virginia G. Kaklamani
Recruiting --> Active, not recruiting | N=210 --> 29 Not yet recruiting --> Recruiting | Initiation date: Jan 2016 --> May 2016
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P3 trial, Metastases: CLEAR trial: Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Jun 23, 2016
P3, N=735, Not yet recruiting, Sponsor: Eisai Inc.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Phase classification, Combination therapy, Metastases: A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment (clinicaltrials.gov) - Jun 16, 2016
P1b/2, N=153, Active, not recruiting, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting | Initiation date: Jan 2016 --> May 2016 Phase classification: P1/2 --> P1b/2
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial: Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers (clinicaltrials.gov) - Jun 9, 2016
P1, N=60, Completed, Sponsor: Eisai Inc.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - Jun 1, 2016
P2, N=40, Recruiting, Sponsor: National University Hospital, Singapore
Phase classification: P1/2 --> P1b/2 Not yet recruiting --> Recruiting
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Trial initiation date, Trial primary completion date: A Study in Subjects With Recurrent Malignant Glioma (clinicaltrials.gov) - May 23, 2016
P2, N=151, Completed, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Terminated --> Completed | Initiation date: Aug 2010 --> Nov 2010 | Trial primary completion date: Dec 2013 --> Mar 2013
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma (clinicaltrials.gov) - May 23, 2016
P2, N=32, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date: Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma (clinicaltrials.gov) - May 18, 2016
P1/2, N=99, Recruiting, Sponsor: Eisai Limited
Terminated --> Completed | Initiation date: Aug 2010 --> Nov 2010 | Trial primary completion date: Dec 2013 --> Mar 2013 Trial primary completion date: Dec 2017 --> Jun 2018
- ||| Enrollment open, Phase classification, Monotherapy, Metastases: Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) (clinicaltrials.gov) - May 18, 2016
P1, N=70, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Dec 2017 --> Jun 2018 Not yet recruiting --> Recruiting | Phase classification: P1/2 --> P1
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile (clinicaltrials.gov) - May 18, 2016
P2, N=210, Recruiting, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting | Phase classification: P1/2 --> P1 Not yet recruiting --> Recruiting
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date: REFLECT: A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - May 9, 2016
P3, N=954, Active, not recruiting, Sponsor: Eisai Limited
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2016 --> Dec 2016
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date, Metastases: Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - May 6, 2016
P1, N=18, Recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Apr 2016 --> Dec 2016 Trial primary completion date: Aug 2016 --> Jan 2017
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial: Post-Marketing Surveillance of Lenvima in Korean Patients (clinicaltrials.gov) - May 6, 2016
P=N/A, N=3000, Not yet recruiting, Sponsor: Eisai Korea Inc.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Enrollment change: Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung (clinicaltrials.gov) - Apr 20, 2016
P2, N=25, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Trial primary completion date: Aug 2016 --> Jan 2017 Recruiting --> Active, not recruiting | N=20 --> 25
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Enrollment change, Metastases: Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression (clinicaltrials.gov) - Apr 18, 2016
P2, N=133, Completed, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting | N=20 --> 25 Active, not recruiting --> Completed | N=167 --> 133
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date: A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) (clinicaltrials.gov) - Apr 6, 2016
P2, N=76, Not yet recruiting, Sponsor: Eisai Inc.
Active, not recruiting --> Completed | N=167 --> 133 Initiation date: Feb 2016 --> May 2016